NeuBase Therapeutics, Inc.
Pagina dedicata companiei NeuBase Therapeutics, Inc. listata cu simbolul US.NBSE
Descriere companie
NeuBase Therapeutics, Inc. (https://www.neubasetherapeutics.com/) is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
Grafic actiuni companie